With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.7787-70-4,Copper(I) bromide,as a common compound, the synthetic route is as follows.
General procedure: 0.018g (0.182mmol) of CuCl was added to 0.340g (0.205mmol) of [PPh4]2[1] dissolved in 20mL of MeCN solution. After stirring the resultant solution for 1hat RT, the yellowish brown solution formed, which was filtered, and solvent was removed in vacuo. The precipitate was washed with Et2O and extracted with THF, then recrystallized with Et2O/MeOH/THF to give [PPh4]2[2a] (0.250g, 0.143mmol, 79% based on CuCl). Similarly, under the same reaction conditions, using CuBr and CuI, we have isolated a yellowish brown solid of [PPh4]2[2b] (96% based on CuBr) and [PPh4]2[2c] (71% based on CuI), respectively, upon crystallization from Et2O/THF.
7787-70-4 Copper(I) bromide 24593, acopper-catalyst compound, is more and more widely used in various.
Reference£º
Article; Shieh, Minghuey; Miu, Chia-Yeh; Liu, Yu-Hsin; Chu, Yen-Yi; Hsing, Kai-Jieah; Chiu, Jung-I; Lee, Chung-Feng; Journal of Organometallic Chemistry; vol. 815-816; (2016); p. 74 – 83;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”